Aliases & Classifications for Cardiac Arrhythmia

MalaCards integrated aliases for Cardiac Arrhythmia:

Name: Cardiac Arrhythmia 58 30 6 17
Adverse Event Associated with Cardiac Arrhythmia 74
Premature Cardiac Complex 74
Extrasystoles 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
cardiac arrhythmia:
Mortality/Aging sudden death
Inheritance autosomal dominant inheritance


External Ids:

OMIM 58 115000
MedGen 43 C0003811
SNOMED-CT via HPO 70 263681008 26636000 88425004

Summaries for Cardiac Arrhythmia

MalaCards based summary : Cardiac Arrhythmia, also known as adverse event associated with cardiac arrhythmia, is related to cardiac conduction defect and long qt syndrome 13, and has symptoms including pulsus trigeminus and bigeminal pulse. An important gene associated with Cardiac Arrhythmia is TANGO2 (Transport And Golgi Organization 2 Homolog), and among its related pathways/superpathways are Circadian entrainment and Aldosterone synthesis and secretion. The drugs Methadone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and kidney, and related phenotypes are abnormality of the nervous system and polymorphic and polytopic ventricular extrasystoles

Description from OMIM: 115000

Related Diseases for Cardiac Arrhythmia

Diseases related to Cardiac Arrhythmia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 cardiac conduction defect 31.9 KCNH2 KCNQ1 RYR2 SCN5A
2 long qt syndrome 13 31.6 KCNH2 KCNQ1 SCN5A
3 long qt syndrome 9 31.6 KCNJ2 SCN5A
4 brugada syndrome 1 31.0 KCNH2 SCN5A
5 long qt syndrome 12 30.9 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
6 long qt syndrome 3 30.7 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
7 familial short qt syndrome 30.5 KCNH2 KCNJ2 KCNQ1
8 ventricular fibrillation, paroxysmal familial, 1 30.2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
9 sudden infant death syndrome 30.1 KCNH2 KCNQ1 RYR2 SCN5A
10 syncope 30.0 KCNH2 KCNJ2 KCNQ1 SCN5A
11 long qt syndrome 2 30.0 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
12 long qt syndrome 5 30.0 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
13 sick sinus syndrome 29.9 CACNA1C RANGRF SCN5A
14 long qt syndrome 1 29.8 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
15 cardiac arrest 29.8 ANK2 KCNH2 KCNQ1 RYR2 SCN5A
16 brugada syndrome 29.5 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1
17 arrhythmogenic right ventricular cardiomyopathy 29.5 ANK2 KCNH2 RYR2 SCN5A
18 hypertrophic cardiomyopathy 29.4 CACNA1C RYR2 SCN5A
19 right bundle branch block 29.3 CACNA1C SCN5A
20 long qt syndrome 6 29.3 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
21 atrioventricular block 29.2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
22 catecholaminergic polymorphic ventricular tachycardia 29.1 ANK2 KCNH2 KCNJ2 RYR2 SCN5A
23 hypokalemic periodic paralysis, type 1 29.1 CACNA1C KCNJ2
24 heart disease 29.0 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 RYR2
25 dilated cardiomyopathy 28.8 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A
26 atrial fibrillation 28.8 ANK2 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
27 jervell and lange-nielsen syndrome 1 28.3 CACNA1C KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
28 long qt syndrome 28.2 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
29 intellectual developmental disorder with cardiac arrhythmia 12.7
30 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 12.6
31 language delay and attention deficit-hyperactivity disorder/cognitive impairment with or without cardiac arrhythmia 12.6
32 cardiac arrhythmia with increased serum creatine kinase 12.5
33 cardiac arrhythmia, ankyrin-b-related 12.4
34 extrasystoles, multiform ventricular, with short stature, hyperpigmentation and microcephaly 12.1
35 ventricular extrasystoles with syncope, perodactyly, and robin sequence 12.1
36 extrasystoles short stature hyperpigmentation microcephaly 12.1
37 ogden syndrome 11.7
38 tango2-related metabolic encephalopathy and arrhythmias 11.4
39 myotonic dystrophy 1 11.3
40 spondylometaphyseal dysplasia, sedaghatian type 11.3
41 hand and foot deformity with flat facies 11.2
42 unclassified myelodysplastic/myeloproliferative disease 11.1
43 carnitine palmitoyltransferase ii deficiency, lethal neonatal 11.1
44 thyrotoxic periodic paralysis 11.1
45 arrhythmogenic right ventricular dysplasia, familial, 1 11.0
46 refsum disease, classic 11.0
47 heterotaxy, visceral, 1, x-linked 11.0
48 cardiomyopathy, infantile histiocytoid 11.0
49 hypomagnesemia 1, intestinal 11.0
50 myotonic dystrophy 2 11.0

Comorbidity relations with Cardiac Arrhythmia via Phenotypic Disease Network (PDN):


Chronic Myocardial Ischemia Familial Atrial Fibrillation
First-Degree Atrioventricular Block Heart Disease
Hypertension, Essential Intermediate Coronary Syndrome
Ischemic Heart Disease Mitral Valve Disease
Sinoatrial Node Disease

Graphical network of the top 20 diseases related to Cardiac Arrhythmia:



Diseases related to Cardiac Arrhythmia

Symptoms & Phenotypes for Cardiac Arrhythmia

Human phenotypes related to Cardiac Arrhythmia:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 33 HP:0000707
2 polymorphic and polytopic ventricular extrasystoles 33 HP:0006696

Symptoms via clinical synopsis from OMIM:

58
Cardiac:
arrhythmia
polymorphic and polytopic ventricular extrasystoles

Neuro:
syncopal attacks

Misc:
sudden death

Clinical features from OMIM:

115000

UMLS symptoms related to Cardiac Arrhythmia:


pulsus trigeminus, bigeminal pulse

MGI Mouse Phenotypes related to Cardiac Arrhythmia:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.56 BVES CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1
2 muscle MP:0005369 9.23 BVES CACNA1C GNB5 KCNH2 KCNJ2 KCNQ1

Drugs & Therapeutics for Cardiac Arrhythmia

Drugs for Cardiac Arrhythmia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 584)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methadone Approved Phase 4 76-99-3 4095
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
4
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
5
Racepinephrine Approved Phase 4,Phase 1,Not Applicable 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4,Phase 1,Not Applicable 51-43-4 5816
7
Amiodarone Approved, Investigational Phase 4,Phase 3,Not Applicable 1951-25-3 2157
8
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
9
Rivaroxaban Approved Phase 4,Phase 3 366789-02-8
10
Milrinone Approved Phase 4,Phase 2 78415-72-2 4197
11
Dobutamine Approved Phase 4,Phase 3,Not Applicable 34368-04-2 36811
12
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
13
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
14
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
15
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
16
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
17 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
18
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
19
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
20
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 437-38-7 3345
21
Atropine Approved, Vet_approved Phase 4,Phase 2 51-55-8, 5908-99-6 174174
22
Ethanol Approved Phase 4,Phase 2,Phase 3,Not Applicable 64-17-5 702
23
Procainamide Approved Phase 4,Phase 3,Not Applicable 51-06-9 4913
24
Ajmaline Approved, Experimental Phase 4 4360-12-7 441080
25
Oxytocin Approved, Vet_approved Phase 4,Early Phase 1,Not Applicable 50-56-6 439302 53477758
26
Carbetocin Approved, Investigational Phase 4,Not Applicable 37025-55-1 71715 16681432
27
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 50-28-2 5757
28
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 1 57-63-6 5991
29
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 1 28014-46-2
30
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 1 35189-28-7 6540478
31
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 1 354812-41-2, 151096-09-2 152946
32
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
33
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
34
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
35
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
36
Phylloquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 84-80-0
37
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
38
Morphine Approved, Investigational Phase 4 57-27-2 5288826
39
Bisoprolol Approved Phase 4,Phase 3 66722-44-9 2405
40
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
41
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
42
Ibutilide Approved Phase 4,Phase 2,Not Applicable 122647-32-9, 122647-31-8 60753
43
Metoprolol Approved, Investigational Phase 4,Not Applicable 37350-58-6, 51384-51-1 4171
44
Magnesium oxide Approved Phase 4,Not Applicable 1309-48-4 14792
45
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-04-2
46
Magnesium citrate Approved Phase 4,Not Applicable 3344-18-1
47
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
48
nivolumab Approved Phase 4 946414-94-4
49
Atorvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 134523-00-5 60823
50
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244

Interventional clinical trials:

(show top 50) (show all 924)
# Name Status NCT ID Phase Drugs
1 Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery Unknown status NCT02056405 Phase 4 Mosapride;Placebo
2 Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit Unknown status NCT02025855 Phase 4 Methadone;Placebo
3 Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery Unknown status NCT02672813 Phase 4
4 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Unknown status NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
5 Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
6 Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy Completed NCT00575523 Phase 4 Atropine;Placebo
7 Ajmaline Utilization in the Diagnosis and Treatment of Cardiac Arrhythmias Completed NCT00702117 Phase 4 flecainide;ajmaline;procainamide
8 Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD Active, not recruiting NCT00729911 Phase 4 Amiodarone
9 Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study Recruiting NCT03716076 Phase 4 Carbetocin
10 Reveal® XT Performance Trial (XPECT) Completed NCT00680927 Phase 4
11 Genetics of QT Response to Moxifloxacin Enrolling by invitation NCT01936480 Phase 4 Moxifloxacin 400mg once time;Placebo
12 Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics Completed NCT01719978 Phase 4 3.6mL 2% Mepivacaine with 1:100,000 epinephrine;Hyaluronidase;Placebo
13 Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145) Recruiting NCT03346057 Phase 4 Sugammadex 2 mg/kg;Sugammadex 4 mg/kg;Sugammadex 16 mg/kg;Neostigmine + Glycopyrrolate
14 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
15 Radiation Exposure Reduction in Supraventricular Tachycardia Ablation Completed NCT01132274 Phase 4
16 Atrial Fibrillation: Canadian Atrial Fibrillation Evaluation (CAFE) Study - Completed NCT00848445 Phase 4
17 Targeted Potassium Levels for Prevention of ICD Therapy Not yet recruiting NCT03833089 Phase 4
18 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
19 Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management Completed NCT02335398 Phase 4 Methadone
20 Bisoprolol Versus Corticosteroid and Bisoprolol Combination for Prophylaxis Against Atrial Fibrillation After on Pump Coronary Artery Bypass Surgery Completed NCT03800264 Phase 4 Bisoprolol
21 Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation Recruiting NCT02426944 Phase 4 NOAC
22 Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation Completed NCT01447862 Phase 4 Brinavess (Vernakalant);Corvert (Ibutilide)
23 Real-Time Assessment of Cryoballoon Pulmonary Vein Isolation Using a Novel Circular Mapping Catheter Completed NCT01448265 Phase 4
24 Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients Completed NCT01085071 Phase 4 Potassium Chloride;Potassium Chloride
25 Anticoagulation in AF Ablation and Effects on Neurocognitive Function Withdrawn NCT02120560 Phase 4
26 Open-Labeled PK-PD Studies of Metoprolol ER Active, not recruiting NCT02417246 Phase 4 Toprol XL;Wockhardt metoprolol;Activas metoprolol
27 Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias Completed NCT00765713 Phase 4
28 Cavotricuspid Isthmusblock and Circumferential Pulmonary Vein Isolation in Patients With Atrial Fibrillation Completed NCT00247780 Phase 4
29 The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects Completed NCT00994006 Phase 4
30 Efficacy of Terlipressin Therapy in Acute Variceal Haemorrhage After EVL Recruiting NCT03584087 Phase 4 Normal Saline;Terlipressin
31 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1 Not yet recruiting NCT03313544 Phase 4 Nivolumab
32 Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI Recruiting NCT02590653 Phase 4 Atorvastatin
33 Atrial Fibrillation and Congestive Heart Failure Trial Completed NCT00597077 Phase 4
34 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit Completed NCT01461733 Phase 4 amiodarone;Placebo
35 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke Completed NCT00924638 Phase 4
36 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation Completed NCT00552084 Phase 4 Fish oil;Placebo
37 A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart Completed NCT02415400 Phase 4 Apixaban;vitamin K antagonist;Acetylsalicylic acid
38 Hemodynamic Responses to Tracheal Intubation Direct Laryngoscope and Videolaryngoscope in Elderly Patients Completed NCT02816775 Phase 4
39 Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction Completed NCT01176968 Phase 4 Eplerenone;Placebo
40 Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque Completed NCT02090075 Phase 4 apixaban;warfarin
41 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter Completed NCT01914926 Phase 4 Metoprolol;Diltiazem
42 Milrinone Versus Dobutamine in Critically Ill Patients Recruiting NCT03207165 Phase 4 Milrinone;Dobutamine
43 ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial Completed NCT01058980 Phase 4
44 (SGB) in Men Treated for Prostate Cancer Improve Hot Flashes Not yet recruiting NCT03796195 Phase 4 .5% Bupivacaine
45 Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation Completed NCT03140631 Phase 4 Protamine Sulfate
46 The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation. Terminated NCT00232271 Phase 4 Clexane
47 Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol Terminated NCT01404767 Phase 4 Esmolol;Metoprolol
48 Study of Optimal Replacement of Thyroxine in the Elderly Completed NCT01647750 Phase 4 Levothyroxine;Levothyroxine
49 Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain Completed NCT03241602 Phase 4 Intraperitoneal lidocaine
50 Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol Completed NCT01174290 Phase 4 Haloperidol decanoate;Placebo

Search NIH Clinical Center for Cardiac Arrhythmia

Genetic Tests for Cardiac Arrhythmia

Genetic tests related to Cardiac Arrhythmia:

# Genetic test Affiliating Genes
1 Cardiac Arrhythmia 30

Anatomical Context for Cardiac Arrhythmia

MalaCards organs/tissues related to Cardiac Arrhythmia:

42
Heart, Testes, Kidney, Brain, Lung, Endothelial, Bone

Publications for Cardiac Arrhythmia

Articles related to Cardiac Arrhythmia:

(show top 50) (show all 785)
# Title Authors Year
1
Temperature variability and hospitalization for cardiac arrhythmia in Brazil: A nationwide case-crossover study during 2000-2015. ( 30594895 )
2019
2
Cardiac arrhythmia considerations of hormone cancer therapies. ( 30698686 )
2019
3
EXPRESS: Pathophysiology, incidence, management and consequences of cardiac arrhythmia in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. ( 30747032 )
2019
4
Amiodarone and acupuncture for cardiac arrhythmia: Study protocol for a systematic review. ( 30762798 )
2019
5
Loperamide induced cardiac arrhythmia successfully supported with veno-arterial ECMO (VA-ECMO), molecular adsorbent recirculating system (MARS) and continuous renal replacement therapy (CRRT). ( 30806091 )
2019
6
Management of asymptomatic arrhythmias: a European Heart Rhythm Association (EHRA) consensus document, endorsed by the Heart Failure Association (HFA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin America Heart Rhythm Society (LAHRS). ( 30882141 )
2019
7
Cardiac arrhythmia and opioids: Be watchful. ( 30885377 )
2019
8
Special Program and Abstract issue of the 14th Annual Congress of the European Cardiac Arrhythmia Society (ECAS). ( 29546583 )
2018
9
Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP). ( 29619247 )
2018
10
Cardiac Arrhythmia Classification by Multi-Layer Perceptron and Convolution Neural Networks. ( 29734666 )
2018
11
Autonomic cardiovascular control and cardiac arrhythmia in two pregnant women with hypertrophic cardiomyopathy: Insights from ICD monitoring. ( 29678624 )
2018
12
Amiodarone for the Successful Management of Caowu Poisoning - Induced Cardiac Arrhythmia. ( 29643705 )
2018
13
Status of cardiac arrhythmia services in Africa in 2018: a PASCAR Sudden Cardiac Death Task Force report. ( 29745966 )
2018
14
Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: A systematic review and meta-analysis. ( 29740922 )
2018
15
Multiclass Classification of Cardiac Arrhythmia Using Improved Feature Selection and SVM Invariants. ( 29692863 )
2018
16
Is exposure to ionising radiation associated with childhood cardiac arrhythmia in the Russian territories contaminated by the Chernobyl fallout? A cross-sectional population-based study. ( 29581199 )
2018
17
Fatal cardiac arrhythmia caused by tumor lysis in a patient with diffuse large B-cell lymphoma upon start of R-CHOP. ( 29531724 )
2018
18
Effects of hawthorn ( Crataegus pentagyna) leaf extract on electrophysiologic properties of cardiomyocytes derived from human cardiac arrhythmia-specific induced pluripotent stem cells. ( 29133340 )
2018
19
European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). ( 29905786 )
2018
20
Kcne4 deletion sex-specifically predisposes to cardiac arrhythmia via testosterone-dependent impairment of RISK/SAFE pathway induction in aged mice. ( 29844497 )
2018
21
Retrospective multi-phase non-contrast-enhanced magnetic resonance angiography (ROMANCE MRA) for robust angiogram separation in the presence of cardiac arrhythmia. ( 29427402 )
2018
22
Design of a hybrid model for cardiac arrhythmia classification based on Daubechies wavelet transform. ( 29877638 )
2018
23
Sex differences in cardiac arrhythmia: a consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society. ( 29961863 )
2018
24
Intellectual developmental disorder with cardiac arrhythmia syndrome in a child with compound heterozygous GNB5 variants. ( 29368331 )
2018
25
Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients. ( 29970732 )
2018
26
Anxiety in children attending a specialist inherited cardiac arrhythmia clinic: a questionnaire study. ( 30234175 )
2018
27
2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). ( 30052888 )
2018
28
Conventional Acupuncture for Cardiac Arrhythmia: A Systematic Review of Randomized Controlled Trials. ( 28432528 )
2018
29
Transesophageal 2D ultrasound to 3D computed tomography registration for the guidance of a cardiac arrhythmia therapy. ( 29992909 )
2018
30
The effect of ambient particle matters on hospital admissions for cardiac arrhythmia: a multi-city case-crossover study in China. ( 30012150 )
2018
31
Effects of Pinocembrin Pretreatment on Connexin 43 (Cx43) Protein Expression After Rat Myocardial Ischemia-Reperfusion and Cardiac Arrhythmia. ( 30022020 )
2018
32
Mutations in voltage-gated L-type calcium channel: implications in cardiac arrhythmia. ( 30027834 )
2018
33
Opioids and Cardiac Arrhythmia: A Literature Review. ( 30071529 )
2018
34
A Heart for Diversity: Simulating Variability in Cardiac Arrhythmia Research. ( 30079031 )
2018
35
Management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing PCI: A Summary of the Joint Consensus Document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). ( 30137444 )
2018
36
Can Intradetrusor OnabotulinumtoxinA Injections Alter Heart Function in Patients with Cardiac Arrhythmia? ( 30205603 )
2018
37
Aconitine-induced cardiac arrhythmia in human induced pluripotent stem cell-derived cardiomyocytes. ( 30233701 )
2018
38
A Case of Cardiac Arrhythmia from Absorption of Normal Saline during Hysteroscopic Myomectomy. ( 30267897 )
2018
39
Machine-Learning Prediction of Drug-Induced Cardiac Arrhythmia: Analysis of Gene Expression and Clustering. ( 30311557 )
2018
40
A Novel Familial Cardiac Arrhythmia Syndrome with Widespread ST-Segment Depression. ( 30380381 )
2018
41
Noninvasive cardiac arrhythmia ablation with particle beams. ( 30421810 )
2018
42
Real-Time Cardiac Arrhythmia Classification Using Memristor Neuromorphic Computing System. ( 30440932 )
2018
43
Statin use is associated with less postoperative cardiac arrhythmia after total hip arthroplasty. ( 30526117 )
2018
44
Pacemaker implantation for treating migraine-like headache secondary to cardiac arrhythmia: A case report. ( 30558049 )
2018
45
Improving medical care and prevention in adults with congenital heart disease-reflections on a global problem-part I: development of congenital cardiology, epidemiology, clinical aspects, heart failure, cardiac arrhythmia. ( 30740318 )
2018
46
Wrapper method for feature selection to classify cardiac arrhythmia. ( 29060691 )
2017
47
Detection and characterization of intermittent complexity variations in cardiac arrhythmia. ( 28746052 )
2017
48
Impact of Supraventricular Tachyarrhythmia in Patients With Inherited Cardiac Arrhythmia. ( 28951021 )
2017
49
Current state of the art for cardiac arrhythmia gene therapy. ( 28642118 )
2017
50
Phosphorylation of serine96 of histidine-rich calcium-binding protein by the Fam20C kinase functions to prevent cardiac arrhythmia. ( 28784772 )
2017

Variations for Cardiac Arrhythmia

ClinVar genetic disease variations for Cardiac Arrhythmia:

6 (show top 50) (show all 204)
# Gene Variation Type Significance SNP ID Assembly Location
1 KCNQ1 NM_000218.2(KCNQ1): c.781-14_781-13delGT deletion Benign/Likely benign rs727503103 GRCh37 Chromosome 11, 2594062: 2594063
2 KCNQ1 NM_000218.2(KCNQ1): c.781-14_781-13delGT deletion Benign/Likely benign rs727503103 GRCh38 Chromosome 11, 2572832: 2572833
3 KCNJ8 NM_004982.3(KCNJ8): c.1182G> C (p.Arg394Ser) single nucleotide variant Uncertain significance rs730880120 GRCh37 Chromosome 12, 21918750: 21918750
4 KCNJ8 NM_004982.3(KCNJ8): c.1182G> C (p.Arg394Ser) single nucleotide variant Uncertain significance rs730880120 GRCh38 Chromosome 12, 21765816: 21765816
5 AKAP9 NM_005751.4(AKAP9): c.4693-11delT deletion Benign rs71292989 GRCh38 Chromosome 7, 92040663: 92040663
6 AKAP9 NM_005751.4(AKAP9): c.4693-11delT deletion Benign rs71292989 GRCh37 Chromosome 7, 91669977: 91669977
7 AKAP9 NM_005751.4(AKAP9): c.7034_7036delGAG (p.Arg2345_Glu2346delinsLys) deletion Likely benign rs786205709 GRCh38 Chromosome 7, 92079167: 92079169
8 AKAP9 NM_005751.4(AKAP9): c.7034_7036delGAG (p.Arg2345_Glu2346delinsLys) deletion Likely benign rs786205709 GRCh37 Chromosome 7, 91708481: 91708483
9 CACNB2 NM_000724.3(CACNB2): c.-110391_-110390insG insertion Benign rs1554759973 GRCh38 Chromosome 10, 18150879: 18150880
10 CACNB2 NM_000724.3(CACNB2): c.-110391_-110390insG insertion Benign rs1554759973 GRCh37 Chromosome 10, 18439808: 18439809
11 RANGRF NM_016492.4(RANGRF): c.52C> T (p.Leu18Phe) single nucleotide variant Uncertain significance rs150856064 GRCh37 Chromosome 17, 8192158: 8192158
12 RANGRF NM_016492.4(RANGRF): c.52C> T (p.Leu18Phe) single nucleotide variant Uncertain significance rs150856064 GRCh38 Chromosome 17, 8288840: 8288840
13 RANGRF NM_016492.4(RANGRF): c.181G> T (p.Glu61Ter) single nucleotide variant Benign rs140704891 GRCh38 Chromosome 17, 8289059: 8289059
14 RANGRF NM_016492.4(RANGRF): c.181G> T (p.Glu61Ter) single nucleotide variant Benign rs140704891 GRCh37 Chromosome 17, 8192377: 8192377
15 ANK2 NM_001148.4(ANK2): c.11683G> C (p.Val3895Leu) single nucleotide variant Uncertain significance rs72556370 GRCh37 Chromosome 4, 114294318: 114294318
16 ANK2 NM_001148.4(ANK2): c.11683G> C (p.Val3895Leu) single nucleotide variant Uncertain significance rs72556370 GRCh38 Chromosome 4, 113373162: 113373162
17 CACNB2 NM_201590.2(CACNB2): c.1044+4_1044+7dupAGTA duplication Conflicting interpretations of pathogenicity rs1456201116 GRCh37 Chromosome 10, 18823160: 18823163
18 CACNB2 NM_201590.2(CACNB2): c.1044+4_1044+7dupAGTA duplication Conflicting interpretations of pathogenicity rs1456201116 GRCh38 Chromosome 10, 18534231: 18534234
19 KCNH2 NM_000238.3(KCNH2): c.3331-13delG deletion Benign rs794728348 GRCh37 Chromosome 7, 150642615: 150642615
20 KCNH2 NM_000238.3(KCNH2): c.3331-13delG deletion Benign rs794728348 GRCh38 Chromosome 7, 150945527: 150945527
21 KCNH2 NM_000238.3(KCNH2): c.3331-14delT deletion Benign rs794728347 GRCh37 Chromosome 7, 150642616: 150642616
22 KCNH2 NM_000238.3(KCNH2): c.3331-14delT deletion Benign rs794728347 GRCh38 Chromosome 7, 150945528: 150945528
23 KCNH2 NM_000238.3(KCNH2): c.3136delC (p.Gln1046Serfs) deletion Pathogenic rs794728472 GRCh37 Chromosome 7, 150644432: 150644432
24 KCNH2 NM_000238.3(KCNH2): c.3136delC (p.Gln1046Serfs) deletion Pathogenic rs794728472 GRCh38 Chromosome 7, 150947344: 150947344
25 KCNH2 NM_000238.3(KCNH2): c.3105_3112dupGGGCGACG (p.Val1038Glyfs) duplication Pathogenic rs794728470 GRCh38 Chromosome 7, 150947368: 150947375
26 KCNH2 NM_000238.3(KCNH2): c.3105_3112dupGGGCGACG (p.Val1038Glyfs) duplication Pathogenic rs794728470 GRCh37 Chromosome 7, 150644456: 150644463
27 KCNH2 NM_000238.3(KCNH2): c.3104_3107dup (p.Asp1037Glyfs) duplication Pathogenic rs794728469 GRCh37 Chromosome 7, 150644461: 150644464
28 KCNH2 NM_000238.3(KCNH2): c.3104_3107dup (p.Asp1037Glyfs) duplication Pathogenic rs794728469 GRCh38 Chromosome 7, 150947373: 150947376
29 KCNH2 NM_000238.3(KCNH2): c.3096_3099dup (p.Pro1034Alafs) duplication Pathogenic rs794728467 GRCh37 Chromosome 7, 150644469: 150644472
30 KCNH2 NM_000238.3(KCNH2): c.3096_3099dup (p.Pro1034Alafs) duplication Pathogenic rs794728467 GRCh38 Chromosome 7, 150947381: 150947384
31 KCNH2 NM_000238.3(KCNH2): c.3079C> A (p.Leu1027Ile) single nucleotide variant Likely benign rs794728346 GRCh37 Chromosome 7, 150644489: 150644489
32 KCNH2 NM_000238.3(KCNH2): c.3079C> A (p.Leu1027Ile) single nucleotide variant Likely benign rs794728346 GRCh38 Chromosome 7, 150947401: 150947401
33 KCNH2 NM_000238.3(KCNH2): c.3079dup (p.Leu1027Profs) duplication Pathogenic rs794728465 GRCh37 Chromosome 7, 150644489: 150644489
34 KCNH2 NM_000238.3(KCNH2): c.3079dup (p.Leu1027Profs) duplication Pathogenic rs794728465 GRCh38 Chromosome 7, 150947401: 150947401
35 KCNH2 NM_000238.3(KCNH2): c.2966-2_2967dup duplication Pathogenic rs794728464 GRCh37 Chromosome 7, 150644601: 150644604
36 KCNH2 NM_000238.3(KCNH2): c.2966-2_2967dup duplication Pathogenic rs794728464 GRCh38 Chromosome 7, 150947513: 150947516
37 KCNH2 NM_000238.3(KCNH2): c.2916_2917dup (p.Leu973Profs) duplication Pathogenic rs794728463 GRCh37 Chromosome 7, 150644742: 150644743
38 KCNH2 NM_000238.3(KCNH2): c.2916_2917dup (p.Leu973Profs) duplication Pathogenic rs794728463 GRCh38 Chromosome 7, 150947654: 150947655
39 KCNH2 NM_000238.3(KCNH2): c.2783_2789delGGGAGAG (p.Gly928Alafs) deletion Pathogenic rs794728457 GRCh38 Chromosome 7, 150947782: 150947788
40 KCNH2 NM_000238.3(KCNH2): c.2783_2789delGGGAGAG (p.Gly928Alafs) deletion Pathogenic rs794728457 GRCh37 Chromosome 7, 150644870: 150644876
41 KCNH2 NM_000238.3(KCNH2): c.2777delC (p.Pro926Argfs) deletion Pathogenic rs794728456 GRCh37 Chromosome 7, 150644882: 150644882
42 KCNH2 NM_000238.3(KCNH2): c.2777delC (p.Pro926Argfs) deletion Pathogenic rs794728456 GRCh38 Chromosome 7, 150947794: 150947794
43 KCNH2 NM_000238.3(KCNH2): c.2053delC (p.Arg685Alafs) deletion Pathogenic rs794728500 GRCh38 Chromosome 7, 150951013: 150951013
44 KCNH2 NM_000238.3(KCNH2): c.2053delC (p.Arg685Alafs) deletion Pathogenic rs794728500 GRCh37 Chromosome 7, 150648101: 150648101
45 KCNH2 NM_000238.3(KCNH2): c.1815delC (p.Ser606Profs) deletion Pathogenic rs794728499 GRCh37 Chromosome 7, 150648666: 150648666
46 KCNH2 NM_000238.3(KCNH2): c.1815delC (p.Ser606Profs) deletion Pathogenic rs794728499 GRCh38 Chromosome 7, 150951578: 150951578
47 KCNH2 NM_000238.3(KCNH2): c.1201_1204dup (p.His402Profs) duplication Pathogenic rs794728434 GRCh37 Chromosome 7, 150649866: 150649869
48 KCNH2 NM_000238.3(KCNH2): c.1201_1204dup (p.His402Profs) duplication Pathogenic rs794728434 GRCh38 Chromosome 7, 150952778: 150952781
49 KCNH2 NM_000238.3(KCNH2): c.1142delG (p.Gly381Alafs) deletion Pathogenic rs794728497 GRCh37 Chromosome 7, 150649928: 150649928
50 KCNH2 NM_000238.3(KCNH2): c.1142delG (p.Gly381Alafs) deletion Pathogenic rs794728497 GRCh38 Chromosome 7, 150952840: 150952840

Expression for Cardiac Arrhythmia

Search GEO for disease gene expression data for Cardiac Arrhythmia.

Pathways for Cardiac Arrhythmia

Pathways related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.7 CACNA1C GNB5 KCNJ2 KCNQ1 RYR2
2
Show member pathways
12.67 CACNA1C KCNE1 KCNQ1 RYR2 SCN5A
3
Show member pathways
12.34 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 12.16 CACNA1C GNB5 KCNE1 KCNE2 KCNH2 KCNJ2
5 11.88 KCNH2 KCNQ1 RYR2 SCN5A
6
Show member pathways
11.87 KCNE2 KCNJ2 KCNQ1
7
Show member pathways
11.8 KCNH2 KCNJ2 KCNQ1
8
Show member pathways
11.51 CACNA1C KCNE1 KCNE2 KCNQ1 RANGRF SCN5A
9 11.02 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
10 10.97 ANK2 SCN5A
11 10.78 KCNE1 KCNJ2 KCNQ1

GO Terms for Cardiac Arrhythmia

Cellular components related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.81 KCNE1 KCNE2 KCNH2 SCN5A
2 lysosome GO:0005764 9.76 ANK2 KCNE1 KCNE2 KCNQ1
3 membrane raft GO:0045121 9.67 ANK2 KCNE1 KCNQ1
4 caveola GO:0005901 9.58 BVES RANGRF SCN5A
5 intercalated disc GO:0014704 9.56 ANK2 KCNJ2 RANGRF SCN5A
6 Z disc GO:0030018 9.55 ANK2 CACNA1C KCNE1 RYR2 SCN5A
7 T-tubule GO:0030315 9.54 ANK2 KCNJ2 SCN5A
8 smooth endoplasmic reticulum GO:0005790 9.48 KCNJ2 RYR2
9 sarcolemma GO:0042383 9.35 ANK2 BVES CACNA1C RYR2 SCN5A
10 voltage-gated potassium channel complex GO:0008076 9.02 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
11 membrane GO:0016020 10.21 ANK2 BVES CACNA1C GNB5 KCNE1 KCNE2
12 plasma membrane GO:0005886 10.1 ANK2 BVES CACNA1C GNB5 KCNE1 KCNE2

Biological processes related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.97 CACNA1C KCNQ1 RYR2 SCN5A
2 potassium ion transport GO:0006813 9.96 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
3 potassium ion transmembrane transport GO:0071805 9.95 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
4 regulation of ion transmembrane transport GO:0034765 9.91 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
5 cardiac muscle contraction GO:0060048 9.87 KCNH2 KCNQ1 RYR2 SCN5A
6 regulation of membrane potential GO:0042391 9.86 BVES KCNH2 RANGRF
7 cellular response to drug GO:0035690 9.83 KCNE2 KCNH2 KCNQ1
8 positive regulation of potassium ion transmembrane transport GO:1901381 9.83 KCNE1 KCNH2 KCNJ2 KCNQ1
9 potassium ion export across plasma membrane GO:0097623 9.81 KCNE1 KCNE2 KCNH2 KCNQ1
10 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.8 KCNE1 KCNE2 KCNH2 KCNQ1
11 regulation of heart rate GO:0002027 9.8 ANK2 BVES RANGRF RYR2 SCN5A
12 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.78 ANK2 CACNA1C RYR2
13 regulation of membrane repolarization GO:0060306 9.78 KCNE2 KCNH2 KCNJ2 KCNQ1
14 regulation of potassium ion transmembrane transport GO:1901379 9.77 KCNE1 KCNE2 KCNH2
15 regulation of cardiac muscle cell contraction GO:0086004 9.77 ANK2 KCNJ2 SCN5A
16 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.76 CACNA1C KCNJ2 SCN5A
17 membrane repolarization GO:0086009 9.76 KCNE1 KCNE2 KCNH2 KCNQ1
18 atrial cardiac muscle cell action potential GO:0086014 9.75 ANK2 KCNQ1 SCN5A
19 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.73 KCNE1 KCNH2 KCNJ2 KCNQ1
20 cardiac muscle cell action potential involved in contraction GO:0086002 9.72 CACNA1C KCNE1 KCNE2 KCNJ2 SCN5A
21 potassium ion import across plasma membrane GO:1990573 9.7 KCNE2 KCNJ2
22 positive regulation of heart rate GO:0010460 9.7 KCNQ1 RYR2
23 regulation of cardiac muscle contraction GO:0055117 9.69 ANK2 RYR2
24 membrane depolarization during action potential GO:0086010 9.69 KCNH2 SCN5A
25 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.68 KCNE1 KCNE2
26 calcium ion transport into cytosol GO:0060402 9.68 CACNA1C RYR2
27 cell communication by electrical coupling involved in cardiac conduction GO:0086064 9.68 CACNA1C RYR2
28 cellular response to epinephrine stimulus GO:0071872 9.68 KCNQ1 RYR2
29 regulation of ventricular cardiac muscle cell action potential GO:0098911 9.67 CACNA1C RYR2
30 regulation of cardiac muscle contraction by calcium ion signaling GO:0010882 9.67 ANK2 RYR2
31 regulation of sodium ion transmembrane transport GO:1902305 9.66 RANGRF SCN5A
32 regulation of delayed rectifier potassium channel activity GO:1902259 9.65 KCNE1 KCNE2
33 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.65 KCNQ1 SCN5A
34 membrane repolarization during action potential GO:0086011 9.65 KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
35 SA node cell action potential GO:0086015 9.64 ANK2 SCN5A
36 membrane depolarization during AV node cell action potential GO:0086045 9.64 CACNA1C SCN5A
37 membrane depolarization during SA node cell action potential GO:0086046 9.63 ANK2 SCN5A
38 sarcoplasmic reticulum calcium ion transport GO:0070296 9.63 ANK2 RYR2
39 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.63 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 SCN5A
40 membrane depolarization during atrial cardiac muscle cell action potential GO:0098912 9.62 CACNA1C SCN5A
41 regulation of atrial cardiac muscle cell action potential GO:0098910 9.62 ANK2 RYR2
42 regulation of SA node cell action potential GO:0098907 9.61 ANK2 RYR2
43 regulation of heart rate by cardiac conduction GO:0086091 9.56 ANK2 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2
44 ventricular cardiac muscle cell action potential GO:0086005 9.17 ANK2 KCNE1 KCNE2 KCNH2 KCNQ1 RYR2
45 ion transport GO:0006811 10.14 CACNA1C KCNE1 KCNE2 KCNH2 KCNJ2 KCNQ1
46 transmembrane transport GO:0055085 10.06 CACNA1C KCNH2 KCNQ1 RYR2 SCN5A

Molecular functions related to Cardiac Arrhythmia according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 calmodulin binding GO:0005516 9.78 CACNA1C KCNQ1 RYR2 SCN5A
2 ion channel activity GO:0005216 9.76 CACNA1C KCNH2 RYR2 SCN5A
3 potassium channel activity GO:0005267 9.71 KCNE1 KCNE2 KCNH2 KCNQ1
4 scaffold protein binding GO:0097110 9.67 KCNH2 KCNQ1 SCN5A
5 voltage-gated potassium channel activity GO:0005249 9.67 KCNE1 KCNE2 KCNH2 KCNQ1
6 voltage-gated ion channel activity GO:0005244 9.63 CACNA1C KCNE2 KCNH2 KCNJ2 KCNQ1 SCN5A
7 delayed rectifier potassium channel activity GO:0005251 9.62 KCNE1 KCNE2 KCNH2 KCNQ1
8 inward rectifier potassium channel activity GO:0005242 9.61 KCNE2 KCNH2 KCNJ2
9 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.56 KCNE1 KCNE2 KCNH2 KCNQ1
10 potassium channel regulator activity GO:0015459 9.54 KCNE1 KCNE2
11 protein kinase A regulatory subunit binding GO:0034237 9.52 KCNQ1 RYR2
12 protein kinase A catalytic subunit binding GO:0034236 9.51 KCNQ1 RYR2
13 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.26 KCNE1 KCNH2 KCNJ2 KCNQ1
14 ion channel binding GO:0044325 9.17 ANK2 KCNE1 KCNE2 KCNQ1 RANGRF RYR2

Sources for Cardiac Arrhythmia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....